A Phase 1 Study in Healthy Subjects to Evaluate the Safety and Pharmacokinetics of a Human Monoclonal Antibody (S315) Against Diphtheria Toxin

• Published in: The Journal of infectious diseases
• Main Authors: Sullivan-Bólyai, John Z, Allen, Larry B, Cannon, Rebecca, Cohane, Kenya P, Dunzo, Elise, Goldwater, Ronald, StCyr, Kathleen, Wang, Yang, Klempner, Mark S
• Format: Journal Article
• Language: English
• Published: United States 21.11.2024
• Subjects: diphtheria toxin; pharmacokinetics; phase 1 study; safety; human monoclonal antibody

Diphtheria is a recurrent threat with endemic still occurs in many parts of the world. The standard of care is horse serum-derived diphtheria antitoxin (eDAT), which is in critical short supply globally. S315 is a fully human, monoclonal immunoglobulin G1 neutralizing antibody, specific to the recep...